About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Torrent Pharmaceuticals Ltd.
Change Company
BSE Code
500420
ISIN Demat
INE685A01028
Book Value
222.38
NSE Code
TORNTPHARM
Dividend Yield %
0.82
Market Cap
1162306.25
P/E
71.05
EPS
48.34
Face Value
5
1 Week
1 Month
3 Months
6 Months
1 Year
05-Dec-2024
Torrent Pharma enters into agreement with Boehrin...
05-Dec-2024
Torrent Pharma rises on entering into agreement w...
27-Sep-2024
Torrent Pharmaceuticals incorporates Wholly owned...
27-Sep-2024
Torrent Pharmaceuticals trades in green on incorp...
21-Sep-2024
Torrent Pharmaceuticals raises Rs 200 crore throu...
30-Aug-2024
Torrent Pharmaceuticals gets EIR with VAI classif...
30-Aug-2024
Torrent Pharmaceuticals informs about disclosure
30-Aug-2024
Torrent Pharmaceuticals jumps on the BSE
14-Aug-2024
Torrent Pharmaceuticals informs about clarificati...
13-Aug-2024
Torrent Pharmaceuticals informs about change in m...
24-Jul-2024
Torrent Pharmaceuticals reports 21% rise in Q1 co...
18-Jul-2024
Torrent Pharmaceuticals informs about conference ...
13-Jun-2024
USFDA completes inspections at Torrent Pharmaceut...
13-Jun-2024
Torrent Pharmaceuticals informs about details of ...
05-Jun-2024
Torrent Pharmaceuticals enters into patent licens...
Page
1
of
2
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.